Central and Peripheral Nervous Disorders

  • Francesca Pastorelli
  • Valentina Favoni
  • Sabina Cevoli
  • Roberto Michelucci


There is increasing attention on determinants of health including not only the genetic and biological differences between males and females defining what we usually call “sex” but also psychological, environmental, and sociocultural factors that define what is commonly called “gender” and which may affect disproportionally men’s and women’s health.

“Dimorphic neurology” focuses on differences between men and women in the causes, manifestations, response to treatments, and outcomes of neurological diseases.

In these pages the authors focus on the implications of sex, gender, and some of the most frequent neurologic diseases, such as stroke, dementia, epilepsy, migraine, and multiple sclerosis.


  1. 1.
    Rocca WA, Mielke MM, Vemuri P, Miller VM. Sex and gender differences in the causes of dementia: a narrative review. Maturitas. 2014;79(2):196–201.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    US Public Health Service. Agenda for research on women’s health for the 21st century. A report of the Task Force on the NIH Women’s Health Research Agenda for the 21st Century, vol. 5. Bethesda, MD: National Institutes of Health; 1999. (DHHS publication no. (NIH) 99-4389).Google Scholar
  3. 3.
    Institute of Medicine. Women’s health research: progress, pitfalls, and promise. Washington, DC: The National Academies Press; 2010.Google Scholar
  4. 4.
    Woods NF, Tsui AO. Editorial: Epidemiologic approaches to women’s health. Epidemiol Rev. 2014;36:1–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Ahnstedt H, McCullough LD, Cipolla MJ. The importance of considering sex differences in translational stroke research. Transl Stroke Res. 2016;7(4):261–73.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Shekhar S, Travis OK, He X, Roman RJ, Fan F. Menopause and ischemic stroke: a brief review. MOJ Toxicol. 2017;3(4)
  7. 7.
    SPREAD. (Stroke Prevention And Educational Awareness Diffusion) - Ictus cerebrale: linee guida italiane di prevenzione e trattamento - VIII Edizione.Google Scholar
  8. 8.
    Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR, on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Samai AA, Martin-Schild S. Sex differences in predictors of ischemic stroke: current perspectives. Vasc Health Risk Manag. 2015;11:427–36.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Gryglas A, Smigiel R. Migraine and stroke: What’s the link? What to do? Curr Neurol Neurosci Rep. 2017;17:22.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915–26.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Boheme AK, Carr BG, Kasner SE, Albright KC, Kallan MJ, Elkind MSV, Branas CC, Mullen MT. Sex differences in rt-PA utilization at hospitals treating stroke: the national inpatient sample. Front Neurol. 2017;8:500. Scholar
  14. 14.
    Berglund A, Schenk-Gustafsson K, von Euler M. Sex differences in the presentation of stroke. Maturitas. 2017;99:47–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim TD, Jung YH, Caso V, Bushnell CD, Saposnik G, on behalf of the Women’s Disparities Working Group. Countries with women inequalities have higher stroke mortality. Int J Stroke. 2017;12(8):869–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention and care. Lancet. 2017;390(10113):2673–734.PubMedCrossRefGoogle Scholar
  17. 17.
    Bannett D. Public health importance of vascular dementia and Alzheimer’s disease with cerebrovascular disease. Int J Clin Pract Suppl. 2001;(120):41–8.Google Scholar
  18. 18.
    Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer’s and vascular types. BioMed Res Int. 2014;2014:908915, 8 pages.CrossRefGoogle Scholar
  19. 19.
    Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37–48.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015–28.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRefGoogle Scholar
  22. 22.
    IHME. Global burden of disease study 2015 (GBD 2015). Seattle, WA: Institute for Health Metrics and Evaluation; 2016.Google Scholar
  23. 23.
    Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87.PubMedCrossRefGoogle Scholar
  26. 26.
    Granella F, Sances G, Allais G, Nappi RE, Tirelli A, Benedetto C, Brundu B, Facchinetti F, Nappi G. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707–16.PubMedCrossRefGoogle Scholar
  27. 27.
    WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.Google Scholar
  28. 28.
    Ripa P, Ornello R, Degan D, Tiseo C, Stewart J, Pistoia F, Carolei A, Sacco S. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015;7:773–82.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache. 2017;57(2):194–208.PubMedCrossRefGoogle Scholar
  30. 30.
    Allais GB, Rolando S, Benedetto C. La donna emicranica. In: Bonavita V, Bussone G, Casucci G, Frediani F, Manzoni GC, editors. Le Cefalee- Clinica e Terapia. Milano, Italy: Cortina Editore, press; 2015.Google Scholar
  31. 31.
    Segal BM, Cohen JA, Antel J. Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course. Mult Scler J. 2018;24(1):4–5.CrossRefGoogle Scholar
  32. 32.
    Canto E, Oksenberg JR. Multiple sclerosis genetics. Mult Scler J. 2018;24(1):75–9.CrossRefGoogle Scholar
  33. 33.
    Dunn SE, Lee H, Pavri FR and Zhang MA. Sex-based differences in Multiple Sclerosis (Part I): biology of disease incidence. Curr Topics Behav Neurosci. 2015. Scholar
  34. 34.
    Waubant E. Effect of puberty on multiple sclerosis risk and course. Mult Scler J. 2018;24(1):32–5.CrossRefGoogle Scholar
  35. 35.
    Bove R, Gilmore W. Hormones and MS: risk factors, biomarkers and therapeutic targets. Mult Scler. 2018;24(1):17–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Kotzamani D, Panou T, Mastorodemos V, et al. Rising incidence of Multiple Sclerosis in females associated with urbanization. Neurology. 2012;78:1728–35.PubMedCrossRefGoogle Scholar
  37. 37.
    Dunn SE, Lee H, Pavri FR and Zhang MA. Sex-based differences in Multiple Sclerosis (Part II): rising incidence of Multiple Sclerosis in women and the vulnerability of men to progression of this disease. Curr Topics Behav Neurosci. 2015. Scholar
  38. 38.
    Langer-Gould A, Jun W, Lucas R, Smith J, Gonzales E, Amezcua L, Haraszti S, Chen LH, Quach H, James JA, Barcellos LF, Xiang AH. Epstein-Barr virus, cytomegalovirus and multiple sclerosis susceptibility. A multiethnic study. Neurology. 2017;89:130–7.Google Scholar
  39. 39.
    Degelman ML, Herman KM. Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord. 2017;17:207–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Shoemaker TJ, Mowry EM. A review of vitamin D supplementation as disease-modifying therapy. Mult Scler J. 2018;24(1):6–11.CrossRefGoogle Scholar
  41. 41.
    Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology. 2012;78:867–74.PubMedCrossRefGoogle Scholar
  42. 42.
    Bangar S, Shastri A, El-Sayeh H, Cavanna AE. Women with epilepsy: clinically relevant issues. Funct Neurol. 2016;31(3):127–34.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology. 2003;61(Suppl 2):S2–15.PubMedCrossRefGoogle Scholar
  44. 44.
    Herzog AG. Menstrual disorders in women with epilepsy. Neurology. 2006;66(Suppl 3):S23–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Morrell MJ. Epilepsy in women: the science of why it is special. Neurology. 1999;53(Suppl 1):S42–8.PubMedGoogle Scholar
  46. 46.
    Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry. 1984;47:1279–82.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Herzog AG, Fowler KM, Smithson SD, et al. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology. 2012;78:1959–66.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570571.CrossRefGoogle Scholar
  49. 49.
    Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83:16–29.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Brien MD, Guillebaud J. Contraception for women taking antiepileptic drugs. J Fam Plann Reprod Health Care. 2010;36:239–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Dutton C, Foldvary-Schaefer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management. Int Rev Neurobiol. 2008;83:113–34.PubMedCrossRefGoogle Scholar
  52. 52.
    Hu X, Wang J, Dong W, et al. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97:73–82.PubMedCrossRefGoogle Scholar
  53. 53.
    Zhou JQ, Zhou LM, Chen LJ, et al. Polycystic ovary syndrome in patients with epilepsy: a study in 102 Chinese women. Seizure. 2012;21:729–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008;64:200–11.PubMedCrossRefGoogle Scholar
  55. 55.
    Zelená V, Kuba R, Soška V, et al. Depression as a prominent cause of sexual dysfunction in women with epilepsy. Epilepsy Behav. 2011;20:539–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:133–41.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66:354–60.CrossRefGoogle Scholar
  58. 58.
    Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol. 2006;13:645–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10:CD010236.Google Scholar
  61. 61.
    Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597–605.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696–703.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after utero exposure to antiepileptic drugs. Neurology. 2015;84:1–9.CrossRefGoogle Scholar
  64. 64.
    Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50:1247–55.PubMedCrossRefGoogle Scholar
  65. 65.
    Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46(Suppl 9):117–24.PubMedCrossRefGoogle Scholar
  66. 66.
    Harden CL, Pulver MC, Ravdin L, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402–7.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Johnson EL, Kaplan PW. Caring for transgender patients with epilepsy. Epilepsia. 2017;58(10):1667–72.PubMedCrossRefGoogle Scholar
  2. Katan M, Luft A. Global burden of stroke. Semin Neurol. 2018;38(2):208–11.PubMedCrossRefGoogle Scholar
  3. Kuzma E, Lurida I, Moore SF, Levine DA, Okoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimer’s Dement. 2018;14(11):1416–26.CrossRefGoogle Scholar
  4. Rankin K, Bove R. Caring for women with Multiple Sclerosis across the lifespan. Curr Neurol Neurosci Rep. 2018;18(7):36.PubMedCrossRefGoogle Scholar
  5. Sadr SS, Javanbakht J, Javidan AN, Ghaffarpour M, Khamse S, Naghshband Z. Descriptive epidemiology: prevalence, incidence, sociodemographic factors, socioeconomic domains, and quality of life of epilepsy: an update and systematic review. Arch Med Sci. 2018;14(4):717–24.PubMedGoogle Scholar
  6. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Francesca Pastorelli
    • 1
  • Valentina Favoni
    • 2
  • Sabina Cevoli
    • 3
  • Roberto Michelucci
    • 1
  1. 1.IRCCS Institute of Neurological Sciences of BolognaUOC NeurologiaBolognaItaly
  2. 2.Department of Biomedical and NeuroMotor Sciences (DiBiNeM)Alma Mater Studiorum - University of BolognaBolognaItaly
  3. 3.IRCCS Institute of Neurological Sciences of BolognaUOC Clinica NeurologicaBolognaItaly

Personalised recommendations